Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus. The company is also developing FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea; and FDX104 that has completed Phase II clinical trial for the treatment of chemotherapy-induced rash. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; Mylan N.V.; and Actavis Laboratories. The company was founded in 2003 and is headquartered in Rehovot, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FOMX
CUSIPN/A
Phone972-8931-6233
Debt
Debt-to-Equity RatioN/A
Current Ratio3.72
Quick Ratio3.72
Price-To-Earnings
Trailing P/E Ratio-3.13
Forward P/E Ratio-3.26
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.67 million
Price / Sales61.30
Cash FlowN/A
Price / CashN/A
Book Value$1.83 per share
Price / Book3.01
Profitability
EPS (Most Recent Fiscal Year)($1.76)
Net Income$-65,710,000.00
Net Margins-2,085.71%
Return on Equity-131.84%
Return on Assets-109.88%
Miscellaneous
Employees75
Outstanding Shares40,830,000
Market Cap$252.32 million
Foamix Pharmaceuticals (NASDAQ:FOMX) Frequently Asked Questions
What is Foamix Pharmaceuticals' stock symbol?
Foamix Pharmaceuticals trades on the NASDAQ under the ticker symbol "FOMX."
How were Foamix Pharmaceuticals' earnings last quarter?
Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) issued its quarterly earnings data on Wednesday, August, 8th. The specialty pharmaceutical company reported ($0.46) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.56) by $0.10. The specialty pharmaceutical company earned $0.96 million during the quarter, compared to the consensus estimate of $1.10 million. Foamix Pharmaceuticals had a negative net margin of 2,085.71% and a negative return on equity of 131.84%. View Foamix Pharmaceuticals' Earnings History.
When is Foamix Pharmaceuticals' next earnings date?
What price target have analysts set for FOMX?
2 analysts have issued 1 year price targets for Foamix Pharmaceuticals' shares. Their predictions range from $8.00 to $11.00. On average, they expect Foamix Pharmaceuticals' share price to reach $9.50 in the next year. This suggests a possible upside of 67.0% from the stock's current price. View Analyst Price Targets for Foamix Pharmaceuticals.
What is the consensus analysts' recommendation for Foamix Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Foamix Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Foamix Pharmaceuticals.
Who are some of Foamix Pharmaceuticals' key competitors?
Some companies that are related to Foamix Pharmaceuticals include Chromadex (CDXC), Mediwound (MDWD), Natural Alternatives International (NAII), Pharmacyte Biotech (PMCB), Mannatech (MTEX), China Jo-Jo Drugstores (CJJD), GLG Life Tech (GLGLF), Cyanotech (CYAN), Conversion Labs (CVLB), ImmuDyne (IMMD), FitLife Brands (FTLF), True Drinks (TRUU), Tauriga Sciences (TAUG), Nutra Pharma (NPHC) and Entia Biosciences (ERGO).
Who are Foamix Pharmaceuticals' key executives?
Foamix Pharmaceuticals' management team includes the folowing people:
- Mr. David T. Domzalski, CEO, Director & Pres of Foamix Pharmaceuticals Inc. (Age 51)
- Mr. Meir Eini, Co-Founder & Innovation Advisor (Age 63)
- Mr. Ilan Hadar MBA, CFO & Country Mang. (Age 49)
- Mr. Yohan Hazot, VP of Pharmaceutical Devel. (Age 35)
- Ms. Mutya Harsch, Gen. Counsel & Sr. VP of Legal Affairs
Has Foamix Pharmaceuticals been receiving favorable news coverage?
Media stories about FOMX stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Foamix Pharmaceuticals earned a news impact score of 0.18 on Accern's scale. They also assigned media coverage about the specialty pharmaceutical company an impact score of 46.57 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View Recent Headlines for Foamix Pharmaceuticals.
Who are Foamix Pharmaceuticals' major shareholders?
Foamix Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Orbimed Advisors LLC (9.91%), Baker BROS. Advisors LP (3.65%), Citadel Advisors LLC (1.24%), Handelsbanken Fonder AB (0.96%), Millennium Management LLC (0.82%) and ARK Investment Management LLC (0.26%). Company insiders that own Foamix Pharmaceuticals stock include David Domzalski, Iain Stuart, Meir Eini, Russell P Elliott and Stanley Hirsch. View Institutional Ownership Trends for Foamix Pharmaceuticals.
Which institutional investors are selling Foamix Pharmaceuticals stock?
FOMX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Baker BROS. Advisors LP. Company insiders that have sold Foamix Pharmaceuticals company stock in the last year include David Domzalski, Iain Stuart, Meir Eini, Russell P Elliott and Stanley Hirsch. View Insider Buying and Selling for Foamix Pharmaceuticals.
Which institutional investors are buying Foamix Pharmaceuticals stock?
How do I buy shares of Foamix Pharmaceuticals?
Shares of FOMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Foamix Pharmaceuticals' stock price today?
One share of FOMX stock can currently be purchased for approximately $5.69.
How big of a company is Foamix Pharmaceuticals?
Foamix Pharmaceuticals has a market capitalization of $252.32 million and generates $3.67 million in revenue each year. The specialty pharmaceutical company earns $-65,710,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Foamix Pharmaceuticals employs 75 workers across the globe.
How can I contact Foamix Pharmaceuticals?
Foamix Pharmaceuticals' mailing address is 2 HOLZMAN ST. WEIZMANN SCIENCE PARK, REHOVOT L3, 76704. The specialty pharmaceutical company can be reached via phone at 972-8931-6233 or via email at [email protected]
MarketBeat Community Rating for Foamix Pharmaceuticals (NASDAQ FOMX)
MarketBeat's community ratings are surveys of what our community members think about Foamix Pharmaceuticals and other stocks. Vote "Outperform" if you believe FOMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
